According to a report by Intel Market Research, the global PET Nuclear Imaging Devices Market was valued at USD 1.34 billion in 2025, estimated at USD 1.40 billion in 2026, and projected to reach USD 2.05 billion by 2034, representing a 4.8% CAGR during 2026–2034. The market covers positron emission tomography systems used for molecular and metabolic imaging across oncology, cardiology, neurology, theranostics and clinical research. PET/CT remains the dominant architecture because it combines molecular information with anatomical localization in a single examination.
Explore the full report: https://www.intelmarketresearch.com/pet-nuclear-imaging-devices-2025-2032-390-1182
Why Is Demand Increasing?
- Continued oncology demand: PET/CT remains a foundational imaging platform for cancer diagnosis, staging, treatment planning and response assessment. Continued cancer-care demand supports scanner utilization in tertiary hospitals and cancer centers.
- Expansion of radiotracer applications: Newer PET tracers are extending utilization beyond traditional FDG oncology. PSMA imaging, amyloid PET and cardiac PET are creating additional applications across prostate cancer, neurology and cardiovascular imaging.
- Growth of theranostics and precision imaging: PET is increasingly used to identify patients for radiopharmaceutical therapies and quantify disease burden before or during treatment, increasing the value of advanced PET/CT systems and quantitative software.
Industry Watch: Long-Axial-FOV and AI Reshape PET Imaging
PET device development is increasingly focused on sensitivity, speed, axial coverage and software-enabled workflows. Long-axial-field-of-view systems are moving into clinical commercialization, with GE HealthCare receiving CE Mark for its 128 cm Omni total-body PET/CT in November 2025. Siemens Healthineers also received FDA clearance for its second-generation Biograph One PET/MR in January 2026. Digital detectors and faster time-of-flight performance are supporting shorter acquisitions and lower administered activity, while AI-assisted reconstruction, automated positioning and quantitative lesion-analysis software are becoming integrated into clinical workflows. Dynamic PET and kinetic modeling are also emerging areas, reflecting a shift toward more quantitative molecular imaging rather than static uptake assessment alone.
Segmentation Highlights
- By Type: Standalone PET, PET/CT and PET/MRI. PET/CT is the leading product type, accounting for approximately 82% of 2025 market revenue.
- By Application: Hospitals, Third-party Imaging Centers and Other Settings. Hospitals lead with approximately 72% of 2025 revenue.
- By Clinical Use: Oncology, Cardiology, Neurology and Theranostics/Research.
- By Technology Direction: Digital PET detectors, time-of-flight PET, long-axial-field-of-view systems, PET/MR and AI-enabled quantitative software.
- By Imaging Platform: PET/CT is expected to retain its dominant position, while PET/MR remains concentrated in academic and specialist centers.
Regional Outlook
- North America: Largest regional market, accounting for approximately 45% of global PET device revenue in 2025. High oncology imaging volumes, radiopharmacy infrastructure, reimbursement pathways and adoption of new tracers support its position.
- Asia-Pacific: Fastest-growing region, with a projected 6.2% CAGR through 2034. China, Japan, South Korea, India and Southeast Asia are expanding cancer-care infrastructure, cyclotron networks and advanced imaging capacity.
- Europe: The second-largest market, supported by nuclear-medicine infrastructure, universal healthcare systems and adoption of advanced hybrid and total-body imaging technologies.
- South America: PET utilization is concentrated in oncology and tertiary care, with private imaging networks supporting expansion while equipment costs and radiotracer availability remain considerations.
- Middle East & Africa: Gulf countries are investing in advanced cancer and theranostics programs, although access remains constrained in several markets by capital requirements, cyclotron availability and specialist workforce limitations.
Download the free sample report: https://www.intelmarketresearch.com/download-free-sample/1182/pet-nuclear-imaging-devices-2025-2032-390
Why This Market Matters
PET nuclear imaging is becoming increasingly important as molecular imaging moves beyond conventional oncology applications. The expansion of PSMA, amyloid and cardiac tracers is creating additional clinical pathways, while theranostics is strengthening the role of PET in patient selection and treatment monitoring.
Technology development is simultaneously changing the economics and capabilities of PET systems. Digital detectors, improved time-of-flight performance and longer axial coverage can support faster examinations, lower-dose protocols and more quantitative imaging. These developments are increasing the importance of software, radiopharmaceutical compatibility and workflow integration alongside scanner hardware.
Competitive Landscape
- Siemens Healthineers: Competes through the Biograph PET/CT family, Biograph Trinion and Biograph One PET/MR, with emphasis on digital detectors, time-of-flight performance and whole-body imaging.
- GE HealthCare: Expanding its Omni PET/CT platform, total-body coverage, deep-learning reconstruction and MIM quantitative software.
- Philips Healthcare: Maintains an established PET/CT position through its digital Vereos platform and clinical imaging installed base.
- United Imaging Healthcare: Competes through advanced digital and total-body PET platforms and expanded access to molecular imaging technologies.
- Canon Medical Systems Corporation: Participates in the market through molecular-imaging systems and specialized PET configurations.
View the full report: https://www.intelmarketresearch.com/pet-nuclear-imaging-devices-2025-2032-390-1182
Frequently Asked Questions
What is the PET Nuclear Imaging Devices Market size and forecast?
The market was valued at USD 1.34 billion in 2025 and is estimated at USD 1.40 billion in 2026. It is projected to reach USD 2.05 billion by 2034 at a 4.8% CAGR during 2026–2034.
Which region leads the PET Nuclear Imaging Devices Market?
North America was the largest regional market in 2025, accounting for approximately 45% of global revenue. Asia-Pacific is expected to record the fastest growth at 6.2% CAGR through 2034.
What are the major trends shaping the market?
Key trends include digital detectors, faster time-of-flight performance, long-axial-field-of-view PET, total-body imaging, PET/MR, AI-assisted reconstruction, quantitative software, cardiac PET, new radiotracers and theranostic workflows.
What Does the Full Report Cover?
The full report provides detailed market sizing and forecasting for PET nuclear imaging devices across standalone PET, PET/CT and PET/MRI platforms. It examines hospitals, third-party imaging centers and other applications, alongside oncology, cardiology, neurology and theranostics/research use cases. The study provides regional and country-level analysis covering North America, Europe, Asia-Pacific, South America and the Middle East & Africa. It also evaluates competitive positioning, manufacturer revenues, sales, pricing, production capacity, market shares and company developments. Additional coverage includes digital detector technology, total-body PET, PET/MR, AI-enabled software, radiotracer expansion, regulatory developments, reimbursement and market dynamics.
View the complete report: https://www.intelmarketresearch.com/pet-nuclear-imaging-devices-2025-2032-390-1182
Download the free sample: https://www.intelmarketresearch.com/download-free-sample/1182/pet-nuclear-imaging-devices-2025-2032-390
About Intel Market Research
Intel Market Research (IMR) provides quantified market intelligence and research reports covering global industries, technologies and emerging business sectors. Its reports examine market size, segmentation, competitive landscapes, regional developments, technology trends and industry outlooks to support business and strategic decision-making.
Contact
Website: www.intelmarketresearch.com
Asia-Pacific: +91 9169164321
